In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...
Hosted on MSN23h
FDA removes clinical hold on Entrada’s Duchenne therapyEntrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback